Endocrine Abstracts

Background: Graves’ ophthalmopathy (GO) is an autoimmune disease that affects particularly the retrobulbar soft tissues and represents the most common extrathyroidal manifestation of Graves’ disease (GD). Some studies suggest that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation, moreover we have no studies that focus the trend of clinical presentation of GO in the last decade on the population of our area.<p ...

Introduction: Oxidative stress (OX) plays a role in the pathogenesis of moderate to severe Graves’ ophthalmopathy (AMS-GO).Aim: We evaluated the impact of clinical conditions related to OX on the outcome of parenteral glucocorticoids (PGLUC) therapy in AMS-GO.Methods: We retrospectively evaluated patients with AMS-GO treated with PGLUC from January 2013 to May 2022. GO clinical evaluation was performed at baseline, at 6 (W6), ...

Introduction: Parenteral corticosteroids (PC) are effective for the treatment of active moderate to severe (AMS) Graves’orbitopathy(GO). A correlation of GO activity with cholesterol has been described. No evidences are available about cholesterol levels and the clinical efficacy of PC in AMS-GO.Aim: Was to detect the predictive role of cholesterol on medium term clinical outcome of PC therapy in AMS-GO.Methods: We studied 87...

Background: Graves’ disease (GD) is an autoimmune disorder of thyroid gland and is the first cause of hyperthyroidism. Radioactive iodine (RAI) therapy is the most used second- line treatment after failure of anti-thyroid drugs. The optimal RAI’s activity to be administered may be predetermined or calculated. Whether the latter is better is still a matter of debate.Aim: To compare the risk of persistent hyperthyroidism in GD patients treated wi...

Background: The 2022 WHO Classification of Endocrine and Neuroendocrine Tumors has introduced, as other neuroendocrine neoplasms, new pathological features to classify medullary thyroid carcinoma (MTC) in low/high grade. However, whether it can be reliable in clinical practice should be confirm by further studies.Aim: To verify the predictive value of the 2022 WHO grading system in patients with MTC.Materials and Methods: Tumor tis...

Background: Tyrosine kinase inhibitors (TKIs) are modern antineoplastic molecules widely used in the medical treatment of many cancers including iodine refractory differentiated thyroid carcer (DTC) and advanced medullary thyroid cancer (MTC). In patients with thyroid gland, TKIs frequently cause a destructive and/or autoimmune thyroiditis with consequent hypothyroidism. However, authors have reported unexpected TSH increase or hypothyroidism even in patients with total thyroi...